Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection

Introduction: Botulinum toxins type-A (BTX-A) including onabotulinumtoxinA (Botox Cosmetic®), abobotulinumtoxin A (Dysport®), and incobotulinumtoxinA (Xeomin®) have regulatory approval and are widely used as a highly effective non-surgical treatment for dynamic facial wrinkles. BTX-A injections have become a mainstay in aesthetic medicine due to their minimally invasive nature, predictable results, and relatively low risk of complications.

Purpose: Optimizing post-BXT-A skincare is crucial for maximizing results and overall skin health. This randomized double-blind vehicle-controlled, split-face study investigated a novel neuropeptide serum designed to complement BTX-A injections in a postprocedural setting.

Methods: This is a 10-week, split-face, double-blind, vehicle-controlled randomized study designed to assess the efficacy and tolerability of a topical neuropeptide serum compared to vehicle control as pre- and post-procedural skincare around onabotulinumtoxinA injections in subjects with mild-to-moderate facial lines, facial wrinkles, and rough skin. At pre-treatment, subjects applied either neuropeptide serum or vehicle to one-half of the face randomized in conjunction with moisturizer, cleanser and sunscreen for 14 days. At baseline, subjects received on-label onabotulinumtoxinA injections for glabella and lateral canthal lines, post-injection subjects continued their randomized skincare regimen. Clinical efficacy live grading was assessed at pre-treatment, baseline, weeks 2, 4 and 8. Tolerance and subject self-assessments were conducted during the study.

Results: The novel neuropeptide serum demonstrated statistically significant improvement (p < 0.05) compared to vehicle in 18 facial  attributes assessed by the clinical dermatologist, including forehead wrinkles, global fine lines, smoothness and radiance at 8 weeks  post BTX-A injection. Additionally, no tolerability concerns were observed by either the investigator or subjects. Compared to vehicle,  the neuropeptides serum’s statistical benefits can be seen as early as 2 weeks prior to BTX-A injection.

Conclusion: The study demonstrated that the neuropeptide serum is an effective complementary product that can be used with BTXA treatments to achieve enhanced results.